These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8144 related articles for article (PubMed ID: 2257565)

  • 21. [Interferons, interleukin-2 and tumor necrosis factor. New approaches to cancer therapy].
    Oettgen HF
    Arzneimittelforschung; 1987 Feb; 37(2A):251-5. PubMed ID: 2436634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current possibilities in immunotherapy of cancer].
    von Fliedner V
    Schweiz Med Wochenschr; 1987 Feb; 117(7):243-8. PubMed ID: 3551061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rational bases for new approaches to the therapy of pediatric solid tumors: immunotherapy and gene therapy].
    Pistoia V; Prigione I; Facchetti P; Corrias MV
    Pediatr Med Chir; 1994; 16(3):219-25. PubMed ID: 7971443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent trends in cancer treatment using cytokines].
    Urushizaki I
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):897-905. PubMed ID: 2471455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunotherapy of malignant diseases].
    Dorval T; Michon J; Tartour E; Fridman WH
    Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
    Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
    Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of interleukin-2 inhalation therapy.
    Huland E; Heinzer H; Huland H; Yung R
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.
    Wojtowicz-Praga S
    J Immunother; 1997 May; 20(3):165-77. PubMed ID: 9181454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Principles of treatment with cells called "LAK" cells].
    Hercend T; Triebel F
    Bull Cancer; 1988; 75(9):879-84. PubMed ID: 3264731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cytokines in the clinic].
    Obrist R
    Helv Chir Acta; 1990 Jan; 56(5):683-8. PubMed ID: 2182570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New concepts in the immunotherapy of neoplasms.
    Rosato FE; Miller EE; Rosato EF
    Compr Ther; 1975 Aug; 1(4):15-23. PubMed ID: 1220910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.
    Waldmann TA
    Cancer Immunol Res; 2015 Mar; 3(3):219-27. PubMed ID: 25736261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospects for immunotherapy.
    Woodruff MF
    Dev Biol Stand; 1977 Apr 13-15; 38():573-80. PubMed ID: 608549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphokines and cytokines.
    Wagstaff J
    Cancer Chemother Biol Response Modif; 1991; 12():165-92. PubMed ID: 1718375
    [No Abstract]   [Full Text] [Related]  

  • 40. IL2 treatment for cancer: from biology to gene therapy.
    Foa R; Guarini A; Gansbacher B
    Br J Cancer; 1992 Dec; 66(6):992-8. PubMed ID: 1457368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 408.